Titel
Phase III Clincal Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrom 2018
Indikation
- Myeloid Leukemia (ML) or Myelodysplastic Syndrome (MDS), according to WHO
- Trisomy 21: Down syndrome or mosaic
Art der Studie
Therapiestudie, Interventionell, Phase III
Therapielinie
Erstlinientherapie
Hauptprüfer am Zentrum (PI)
PD Dr. med. Jessica Höll
Ansprechpartner
PD Dr. med. Jessica Höll
Telefon: 0345/ 557 2467
Mail: jessica.hoell@uk-halle.de